Patent appeal board takes up Ozempic challenge
The US Patent and Trademark Office’s Patent Trial and Appeal Board has agreed to take another look at a patent covering certain strengths of Novo Nordisk’s GLP-1 blockbuster Ozempic, according to generic drug company Viatris.
The challenge was brought by Mylan Pharmaceuticals, now part of Viatris, which also requested a review of two other patents protecting semaglutide. The board denied those requests earlier this week, but has agreed to review the third patent, number ‘462, a Viatris spokesperson said via email on Wednesday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
